Active, not recruitingPhase 2NCT04850599
Isatuximab, Carfilzomib, and Pomalidomide for the Treatment of Relapsed or Refractory Multiple Myeloma
Studying Anorectal malformation
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- OHSU Knight Cancer Institute
- Principal Investigator
- Rebecca W SilbermannOHSU Knight Cancer Institute
- Intervention
- Carfilzomib(drug)
- Enrollment
- 5 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2022 – 2029
Study locations (1)
- OHSU Knight Cancer Institute, Portland, Oregon, United States
Collaborators
Oregon Health and Science University · Sanofi
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04850599 on ClinicalTrials.govOther trials for Anorectal malformation
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT07441083Efficacy and Safety of Shatavari Root Extract in Women's Sexual WellnessSF Research Institute, Inc.
- RECRUITINGPHASE1NCT07545967Re-radiotherapy Combined With Chidamide for the Treatment of Recurrent Head and Neck Squamous Cell Carcinoma After RadiotherapyWest China Hospital
- RECRUITINGNCT07438691Outcomes in ARMs: Comparison Between Surgical Techniques in Patients With Perineal or Vestibular Fistula - a Multicenter Italian StudyMeyer Children's Hospital IRCCS
- RECRUITINGNCT07174388A Study in Non-Small Cell Lung CancerN-Power Medicine
- RECRUITINGPHASE2, PHASE3NCT07369739Golidocitinib Combined With Selinexor for CAEBVDBeijing Friendship Hospital
- RECRUITINGNANCT07366476Effectiveness of Electrical Stimulation and Biofeedback on Fecal Incontinence in Children With Repaired Anorectal MalformationSinai University
- RECRUITINGPHASE2NCT07311577Disitamab Vedotin Combined With Platinum and Bevacizumab as First-Line and Maintenance Therapy for HER2-Expressing, HRD-Negative High-Risk Ovarian Cancer: A Multicenter, Non-Randomized, Single-Arm Phase II Clinical StudyJiangsu Cancer Institute & Hospital
- RECRUITINGNANCT07263451Safety and Feasibility of IRE for Early-stage Breast Cancer: a Prospective, Open-Label, Single-Arm, Exploratory StudyTian'an Jiang